Array BioPharma initiates MEK162 Phase MILO study

theflyonthewall.com

Array BioPharma announced that a $5M milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer. The study, called MILO is a multinational, randomized Phase 3 trial and will evaluate MEK162 against physician's choice of standard chemotherapy treatments in 300 patients with recurrent or persistent LGSOC following at least one prior platinum-based chemotherapy regimen and no more than three lines of prior chemotherapy regimens. The primary endpoint is progression-free survival, and the key secondary endpoint is overall survival. Array invented MEK162 and licensed worldwide rights to develop and commercialize the drug to Novartis in April 2010. Novartis recently detailed plans to initiate Phase 3 trials of MEK162 in both NRAS- and BRAF-mutant melanoma. All three trials will be conducted as part of the Novartis/Array co-development agreement under which costs are capped annually and in total for Array.

View Comments (0)